Providing Access to Rezdiffra for NASH and the Therapies to Come | AMCP 2024
At the Academy of Managed Care Pharmacy meeting on April 16, experts discussed the emerging landscape of NASH treatments, focusing on the recent approval of Madrigal’s Rezdiffra. Donna R. Cryer, JD, CEO of Global Liver Institute, highlighted the importance of aligning payer policies with approved therapy labels. At the same time, Stephanie Spence, PharmD, from CareFirst BlueCross BlueShield proposed value-based contracts to address the high cost of the medication. Both emphasized the ongoing need for additional treatments and equitable access in managing NASH.
Sleep Deprivation: A Silent Trigger for Liver Disease
Over one-third of American adults do not meet the recommended seven to eight hours of sleep nightly, unknowingly contributing to the rising incidence of non-alcoholic fatty liver disease (NAFLD). This silent epidemic, largely symptom-free in its early stages, emphasizes the critical need for adequate sleep to maintain liver health.
Noninvasive tests aid in combating liver disease in Southeast Asia
The rising obesity rates in Southeast Asia have contributed to a higher incidence of liver diseases such as NAFLD and NASH. Advancements in blood tests and a better understanding of blood-based biomarkers, diagnosis, and prognosis for these conditions are being revolutionized, allowing for earlier intervention and improved outcomes in regions with limited access to invasive procedures.
EMA considering conditional approval for NASH drugs using intermediate endpoints
The European Medicines Agency (EMA) will consider granting conditional approval for NASH drugs using intermediate endpoints, a decision which will address the high unmet need for these products. The focus outlines a preliminary development strategy for these treatments: Main considerations include non-cirrhotic NASH, fibrosis stages, and cirrhotic NASH. This strategy, which will require ongoing or new studies or additional data collection to maintain authorization, aims to tackle the EU’s absence of approved NASH treatments.
2nd Annual Primary Care NAFLD/NASH Summit Sessions NOW AVAILABLE
In December 2023, GLI was invited to join an educational partnership with the Fatty Liver Alliance for their Second Annual Primary Care NAFLD and NASH Summit. If you missed it, you can now access the session highlights. Visit the platform to access invaluable insights and enhance your expertise in managing this chronic condition.
Upcoming Events
May 13-17: Finnish Liver Week 2024
The Finnish Kidney and Liver Association’s Liver Week, running from May 13th to 17th, 2024, is dedicated to shedding light on the prevalent alcohol consumption habits among Finland’s working-age population. Through expert-led discussions and personal testimonies, the initiative underscores the detrimental effects of alcohol on liver health, the complexities of addiction, and pathways to positive change.
We’re excited to announce that the GLI team will be present at these upcoming conferences:
- May 18-21: Digestive Diseases Week
- June 5-8: EASL Congress 2024
If you’re attending either of these conferences and would like to meet with us, please reach out to info@globalliver.org to schedule a meeting. We look forward to connecting with you!
June 13: Global Fatty Liver Day
June 13 is Global Fatty Liver Day, and action is needed! Conditions like obesity and diabetes raise the risk for fatty liver disease. Early screening is vital. By promoting early detection, we prevent complications like cirrhosis and liver cancer. Act now to prioritize liver health and reduce the need for future transplants. Join us in raising awareness and taking proactive steps for a healthier tomorrow!
